[{"address1": "Bellevue Centre", "address2": "Suite 300 235 -15th Street", "city": "West Vancouver", "state": "BC", "zip": "V7T 2X1", "country": "Canada", "phone": "604 921 1810", "fax": "604 921 1898", "website": "https://briacell.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "BriaCell Therapeutics Corp. operates as a Phase 3 biotechnology company transforming cancer care with its novel cellular immunotherapies. It is conducting a pivotal Phase 3 clinical trial in advanced breast cancer with its Bria-IMT in combination with an immune check point inhibitor. It is also developing personalized off-the-shelf treatments for breast cancer, prostate cancer, and other cancers. The company has a collaboration with Incyte Corporation to evaluate combination of the Bria-IMT. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.", "fullTimeEmployees": 16, "maxAge": 86400, "priceHint": 4, "previousClose": 1.3, "open": 1.3, "dayLow": 1.19, "dayHigh": 1.3, "regularMarketPreviousClose": 1.3, "regularMarketOpen": 1.3, "regularMarketDayLow": 1.19, "regularMarketDayHigh": 1.3, "beta": 1.84, "forwardPE": -1.195, "volume": 92893, "regularMarketVolume": 92893, "averageVolume": 116951, "averageVolume10days": 65570, "averageDailyVolume10Day": 65570, "bid": 0.9216, "ask": 1.54, "bidSize": 200, "askSize": 200, "marketCap": 21850218, "fiftyTwoWeekLow": 1.19, "fiftyTwoWeekHigh": 7.59, "fiftyDayAverage": 1.8198, "twoHundredDayAverage": 3.73785, "currency": "USD", "enterpriseValue": 20646540, "floatShares": 13042449, "sharesOutstanding": 18284700, "sharesShort": 645689, "sharesShortPriorMonth": 685017, "sharesShortPreviousMonthDate": 1713139200, "dateShortInterest": 1715731200, "sharesPercentSharesOut": 0.0404, "heldPercentInsiders": 0.15557, "heldPercentInstitutions": 0.1204, "shortRatio": 15.21, "shortPercentOfFloat": 0.0461, "impliedSharesOutstanding": 18342700, "bookValue": -0.373, "lastFiscalYearEnd": 1690761600, "nextFiscalYearEnd": 1722384000, "mostRecentQuarter": 1714435200, "netIncomeToCommon": -5995956, "trailingEps": -0.37, "forwardEps": -1.0, "lastSplitFactor": "1:300", "lastSplitDate": 1577923200, "enterpriseToEbitda": -0.586, "52WeekChange": -0.8156682, "SandP52WeekChange": 0.26238096, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "BCTX", "underlyingSymbol": "BCTX", "shortName": "BriaCell Therapeutics Corp.", "longName": "BriaCell Therapeutics Corp.", "firstTradeDateEpochUtc": 1331731800, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "4582bc39-2d8c-30ab-8663-2245a7a6ffd9", "messageBoardId": "finmb_262266102", "gmtOffSetMilliseconds": -14400000, "currentPrice": 1.195, "targetHighPrice": 18.0, "targetLowPrice": 18.0, "targetMeanPrice": 18.0, "targetMedianPrice": 18.0, "recommendationMean": 2.0, "recommendationKey": "buy", "numberOfAnalystOpinions": 1, "totalCash": 935694, "totalCashPerShare": 0.051, "ebitda": -35252612, "quickRatio": 0.141, "currentRatio": 0.818, "returnOnAssets": -1.2271299, "freeCashflow": -17953906, "operatingCashflow": -31009404, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-06-24"}]